Moderna shares plunge after cutting research budget
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/24/2026
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Oil drops more than $2 despite new US sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Wattmore and Eos Energy strike non-exclusive storage software deal
- Grand Canyon Education places CFO on leave amid stock trade probe
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Funds sell $44bn in semiconductors on AI concerns
- RUM Group signs $13.7 billion GPU services deal, issues warrants
Moderna R&D Day Highlights Progress and Strategic Priorities
September 12, 2024 6:02 AM EDTFocuses on ten product approvals through 2027
Expects to submit next-generation COVID vaccine for approval in 2024
Expects to submit flu/COVID combination vaccine for approval in 2024
Announces positive Phase 3 results for its RSV vaccine for high-risk adults aged 18 to 59; expects to submit sBLA for U.S. approval in 2024
Announces positive Phase 3 results for its standalone flu vaccine for adults aged 65 and older relative to high-dose licensed comparator
Announces norovirus vaccine advances into Phase 3 study, bringing the total of non-respiratory pivotal... More
Carisma and Moderna Expand Collaboration to Develop Two In Vivo CAR-M Therapies for Autoimmune Diseases
September 10, 2024 7:30 AM EDTBuilding on successful pre-clinical in vivo CAR-M data in oncology, the companies will develop in vivo CAR-M for autoimmune diseases
Moderna nominated two autoimmune disease targets under the collaboration
Carisma is eligible to receive milestones and royalty payments
PHILADELPHIA, Sept. 10, 2024 /PRNewswire/ --Â ... More
